Skip to main content

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Recruiting · Phase 3 · NCT06064877

Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

At a glance

Research payments reported, 2025
$2.8M
U.S. investigators named
27
Sites paid
27
Planned or actual enrollment
410

About the trial

Sponsor
AVEO Pharmaceuticals, Inc.
Tested
Ficlatuzumab (biological), Cetuximab (biological), Placebo (other)
Dates
Started 2024-01-11; completion 2027-11
Results posted
Not yet

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.

From ClinicalTrials.gov, last updated 2026-04-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Aveo Pharmaceuticals, Inc. reported $2.8M in research payments for this study in 2025 (259 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Ut MD Anderson Cancer Center $482,005
  • Dana Farber Cancer Institute $370,835
  • Institute for Cancer Research $260,951
  • Banner Casa Grande Medical Center $196,127
  • Emory University Hospital, GA $166,365
  • University of Kansas Medical Center Research Institute Inc $151,796
  • Moffitt Cancer Center $122,616
  • Ronald Reagan UCLA Medical Center, CA $118,596
  • University of Arizona $106,795
  • Ohio State University $93,670
  • Mary Bird Perkins Cancer Center $92,024
  • Adventhealth Orlando, FL $87,546
  • Virginia Commonwealth University School of Medicine $76,729
  • Oncology Consultants PA $75,793
  • Unv of Pittsburgh Cancer Institute $70,744
  • Medical University of South Carolina $44,221
  • The Feinstein Institute for Medical Research $40,202
  • State of Maryland $38,545
  • University of Cincinnati $36,763
  • Biomedical Research Alliance of New York LLC $34,974
  • Yale University School of Medicine $30,304
  • Chicago Association of Research and Education in Science $30,000
  • University of Illinois Hospital and Clinics, IL $28,266
  • The George Washington University Medical Center $27,837
  • Washington University $20,142
  • The Medical College of Wisconsin $15,743
  • Mainehealth Maine Medical Center, ME $3,035

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.